Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Generali' s low risk, fast growth and high capital returns are underappreciated by the market as it is reaching the end of a multi-year transformation of its risk profile, Jefferies said, raising its ...

Wolters Kluwer has nominated Anjana Harve, currently the EVP and CIO at BJ’s Wholesale Club, for a position on its ...

This is the sort of success story the EU likes to tell about itself. Europe is home to the world’s least corrupt countries, ...

On Tuesday Roche announced the inauguration of its new “Pharma Research and Early Development Centre” at its global ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer’s radar. Jim Cramer often reflects on how he would reform the American ...

The strike appeared to be one of the deadliest carried out by Russian forces since the war began more than 900 days ago, with Russia's Feb. 24, 2022, full-scale invasion. It was the war's ...

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...

Russia launched one of its largest and most deadly missile attacks against Ukraine on Tuesday, killing at least 41 people and injuring at least 180 others. The missile strike targeted the ...

Ukraine took control of hundreds of square miles of Russian territory, captured hundreds of prisoners and destroyed the Kremlin’s initial reinforcements. WSJ explains Kyiv’s biggest attack on ...

Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...